Key Drivers
- Very high gross-margin
- Deep operating losses
- Strong liquidity / low leverage
AIAI Summary
CeriBell's shift to a recurring‑revenue, high‑gross‑margin platform with rising utilization and validated clinical/regulatory progress makes margin leverage and sustainable growth the key investment thesis, but investors should only pay a premium if management consistently delivers above‑guide revenue while materially decelerating OpEx growth and avoiding adverse ITC or supply‑chain outcomes that would necessitate dilution.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high gross-margin
- •Deep operating losses
- •Strong liquidity / low leverage
CBLL combines very high gross margins and low leverage with severe operating losses, persistent cash burn and negative returns, making the current market price look rich versus fundamentals.
Price Behavior
Key Price Behavior Insights:
- •Below 21‑day SMA
- •Near recent low
- •Neutral momentum
CBLL is mildly bearish after closing below its last-month 21‑day SMA (~$18.74) and nearer the recent low, with neutral RSI (~54) leaving room for consolidation unless it reclaims the SMA or breaks the March low.
Declined from $20.22 on 2026-02-20 to $18.52 over the last month
Sentiment & News
Key News Insights:
- •Accelerating revenue
- •Commercial expansion
- •Continued net loss
CeriBell reported accelerating 36% revenue growth to $89M in 2025 and a 2026 guide of ~25–29% while pushing point‑of‑care EEG commercialization into pediatric, neonatal and delirium markets despite ongoing net losses.
The stronger top‑line momentum and clearer commercialization roadmap should support continued multiple expansion and analyst optimism, but sustained profitability is required to validate the rally
Similar Companies in Healthcare
Other companies in the same sector with AI ratings